Cargando…

Efficacy of Huangqi Injection in the Treatment of Hypertensive Nephropathy: A Systematic Review and Meta-Analysis

BACKGROUND: Huangqi injection (HQI) is the extract of Astragalus membranaceus (Fisch.) Bunge, which is widely used in the treatment of a variety of diseases in China. It is supposed to be an important adjuvant therapy for hypertensive nephropathy. OBJECTIVE: To evaluate the efficacy of HQI combined...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, ZhongChi, Qian, LiChao, Niu, RuGe, Yang, Ying, Liu, ChunLing, Lin, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081808/
https://www.ncbi.nlm.nih.gov/pubmed/35547210
http://dx.doi.org/10.3389/fmed.2022.838256
_version_ 1784703073447313408
author Xu, ZhongChi
Qian, LiChao
Niu, RuGe
Yang, Ying
Liu, ChunLing
Lin, Xin
author_facet Xu, ZhongChi
Qian, LiChao
Niu, RuGe
Yang, Ying
Liu, ChunLing
Lin, Xin
author_sort Xu, ZhongChi
collection PubMed
description BACKGROUND: Huangqi injection (HQI) is the extract of Astragalus membranaceus (Fisch.) Bunge, which is widely used in the treatment of a variety of diseases in China. It is supposed to be an important adjuvant therapy for hypertensive nephropathy. OBJECTIVE: To evaluate the efficacy of HQI combined with antihypertensive drugs in the treatment of hypertensive nephropathy. MATERIALS AND METHODS: We systematically searched China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), Wanfang Knowledge Service Platform (WanfangData), Chinese Biomedical Database (CBM), EMBASE, PubMed and Cochrane Library from their inception to April 23st, 2021. All studies were independently screened by two auditors according to the inclusion and exclusion criteria. Randomized controlled trials comparing HQI in combination with antihypertensive drugs vs. antihypertensive drugs alone were extracted. RESULTS: The meta-analysis included 15 studies involving 1,483 participants.The effect of HQI combined with antihypertensive drugs is better than that of antihypertensive drugs alone in regulating hypertensive nephropathy for reducing 24-h urinary total protein (24 h UTP) [WMD=-0.29, 95% CI (−0.40, −0.18), P = 0.000], microalbuminuria (mALB) [WMD = −17.04, 95% CI (−23.14, −10.94), P = 0.000], serum creatinine (SCr) [WMD = −40.39, 95% CI (−70.39, −10.39), P = 0.008], systolic blood pressure (SBP) [WMD = −9.50, 95% CI (−14.64, −4.37), P = 0.000], diastolic blood pressure (DBP) [WMD = −4.588, 95% CI (−6.036, −3.140), P = 0.000], cystatin-C (Cys-c) [WMD = −0.854, 95% CI (−0.99, −0.72), P = 0.000], blood urea nitrogen (BUN) [WMD = −4.155, 95% CI (−6.152, −2.157), P = 0.000]. CONCLUSION: The combination of HQI and antihypertensive drugs is more efficient in improving the related indexes of patients with hypertensive nephropathy than using antihypertensive drugs alone, and a moderate dose of HQI (no more than 30 mL) may benefit more. However, the quality of the methodology is low and the number of samples is small, the results need to be confirmed by more stringent randomized controlled trials.
format Online
Article
Text
id pubmed-9081808
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90818082022-05-10 Efficacy of Huangqi Injection in the Treatment of Hypertensive Nephropathy: A Systematic Review and Meta-Analysis Xu, ZhongChi Qian, LiChao Niu, RuGe Yang, Ying Liu, ChunLing Lin, Xin Front Med (Lausanne) Medicine BACKGROUND: Huangqi injection (HQI) is the extract of Astragalus membranaceus (Fisch.) Bunge, which is widely used in the treatment of a variety of diseases in China. It is supposed to be an important adjuvant therapy for hypertensive nephropathy. OBJECTIVE: To evaluate the efficacy of HQI combined with antihypertensive drugs in the treatment of hypertensive nephropathy. MATERIALS AND METHODS: We systematically searched China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), Wanfang Knowledge Service Platform (WanfangData), Chinese Biomedical Database (CBM), EMBASE, PubMed and Cochrane Library from their inception to April 23st, 2021. All studies were independently screened by two auditors according to the inclusion and exclusion criteria. Randomized controlled trials comparing HQI in combination with antihypertensive drugs vs. antihypertensive drugs alone were extracted. RESULTS: The meta-analysis included 15 studies involving 1,483 participants.The effect of HQI combined with antihypertensive drugs is better than that of antihypertensive drugs alone in regulating hypertensive nephropathy for reducing 24-h urinary total protein (24 h UTP) [WMD=-0.29, 95% CI (−0.40, −0.18), P = 0.000], microalbuminuria (mALB) [WMD = −17.04, 95% CI (−23.14, −10.94), P = 0.000], serum creatinine (SCr) [WMD = −40.39, 95% CI (−70.39, −10.39), P = 0.008], systolic blood pressure (SBP) [WMD = −9.50, 95% CI (−14.64, −4.37), P = 0.000], diastolic blood pressure (DBP) [WMD = −4.588, 95% CI (−6.036, −3.140), P = 0.000], cystatin-C (Cys-c) [WMD = −0.854, 95% CI (−0.99, −0.72), P = 0.000], blood urea nitrogen (BUN) [WMD = −4.155, 95% CI (−6.152, −2.157), P = 0.000]. CONCLUSION: The combination of HQI and antihypertensive drugs is more efficient in improving the related indexes of patients with hypertensive nephropathy than using antihypertensive drugs alone, and a moderate dose of HQI (no more than 30 mL) may benefit more. However, the quality of the methodology is low and the number of samples is small, the results need to be confirmed by more stringent randomized controlled trials. Frontiers Media S.A. 2022-04-25 /pmc/articles/PMC9081808/ /pubmed/35547210 http://dx.doi.org/10.3389/fmed.2022.838256 Text en Copyright © 2022 Xu, Qian, Niu, Yang, Liu and Lin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Xu, ZhongChi
Qian, LiChao
Niu, RuGe
Yang, Ying
Liu, ChunLing
Lin, Xin
Efficacy of Huangqi Injection in the Treatment of Hypertensive Nephropathy: A Systematic Review and Meta-Analysis
title Efficacy of Huangqi Injection in the Treatment of Hypertensive Nephropathy: A Systematic Review and Meta-Analysis
title_full Efficacy of Huangqi Injection in the Treatment of Hypertensive Nephropathy: A Systematic Review and Meta-Analysis
title_fullStr Efficacy of Huangqi Injection in the Treatment of Hypertensive Nephropathy: A Systematic Review and Meta-Analysis
title_full_unstemmed Efficacy of Huangqi Injection in the Treatment of Hypertensive Nephropathy: A Systematic Review and Meta-Analysis
title_short Efficacy of Huangqi Injection in the Treatment of Hypertensive Nephropathy: A Systematic Review and Meta-Analysis
title_sort efficacy of huangqi injection in the treatment of hypertensive nephropathy: a systematic review and meta-analysis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081808/
https://www.ncbi.nlm.nih.gov/pubmed/35547210
http://dx.doi.org/10.3389/fmed.2022.838256
work_keys_str_mv AT xuzhongchi efficacyofhuangqiinjectioninthetreatmentofhypertensivenephropathyasystematicreviewandmetaanalysis
AT qianlichao efficacyofhuangqiinjectioninthetreatmentofhypertensivenephropathyasystematicreviewandmetaanalysis
AT niuruge efficacyofhuangqiinjectioninthetreatmentofhypertensivenephropathyasystematicreviewandmetaanalysis
AT yangying efficacyofhuangqiinjectioninthetreatmentofhypertensivenephropathyasystematicreviewandmetaanalysis
AT liuchunling efficacyofhuangqiinjectioninthetreatmentofhypertensivenephropathyasystematicreviewandmetaanalysis
AT linxin efficacyofhuangqiinjectioninthetreatmentofhypertensivenephropathyasystematicreviewandmetaanalysis